The Precision Peptide Company has signed an agreement with a U.S.-based telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of its peptide products, including BPC-157. This builds on their recent agreement with a U.S. 503A compounding pharmacy to ensure all peptides are compounded domestically. The telehealth platform connects licensed providers across all 50 states and complies with U.S. legal and pharmacy regulations, positioning the company for prescription-based peptide access ahead of a regulatory review by the FDA's Pharmacy Compounding Advisory Committee scheduled for July 2026. This infrastructure prepares the company for potential regulatory changes and commercial deployment in the U.S.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
